hiPSC-RPEs

Preclinical

TThe First Affiliated Hospital with Nanjing Medical University

hiPSC-RPEs is one of 4 therapeutic programs targeting AMD - Age-Related Macular Degeneration. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Recruiting

Competition

Competitive Landscape

3 competitors in AMD - Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Preclinical

1 2

Tarceva

OOSI Pharmaceuticals

Preclinical

1 3

Hipsc-RPE Cells

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

1 4

hiPSC-RPEs

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

AMD - Age-Related Macular Degeneration

NCT07418177

Clinical

Trials by Indication[1]

AMD - Age-Related Macular Degeneration1 trial

Study in Human iPSCs-derived Retinal Pigment Epithelium Cells Transplantation for Advanced (Late-stage) Age-Related Macular Degeneration

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Preclinical·NCT07418177·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for hiPSC-RPEs. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for hiPSC-RPEs. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — The First Affiliated Hospital with Nanjing Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: TThe First Affiliated Hospital with Nanjing Medical University

hiPSC-RPEs

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

AMD - Age-Related Macular Degeneration1 trial

References

Drug Info

Quick Facts

Related News